MedTrace Logo

Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients

NCT01210521 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-08-10

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of vitamin D3 on severe asthmatic patients. Vitamin D3 may alter the response of these patients to conventional steroid therapy, making them more responsive to the latter form of treatment. Patients will be treated daily with an oral dose (2,000 IU) of vitamin D3 for one month and their clinical and serological parameters, and immune function, will be evaluated. Results from pre- and post-vitaminD3 treatment will be compared.

Conditions

Interventions

DRUG

Vitamin D

Vitamin D, (2000IU) will be administered orally, once a day, for one month.

Sponsors & Collaborators

  • Florida Atlantic University

    lead OTHER

Principal Investigators

  • James X Hartmann, PhD · Florida Atlantic University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2016-02-29
Completion
2016-02-29

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01210521 on ClinicalTrials.gov